<div id="readability-page-1"><div>** Alphamab Oncology rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2** Stock hits highest since December 15 after three straight sessions of fall** Company says its JSKN003 has been granted breakthrough therapy designation (BTD) by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer** Adds, &#34;The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate&#34;** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China** YTD, stock surges 207.1%</div></div>

09966

Alphamab Oncology's stock rose 7.1% to HK$10.96, marking its largest one-day gain since October 2, following the U.S. FDA's breakthrough therapy designation for its drug JSKN003, aimed at treating advanced ovarian cancer. This designation highlights the drug's clinical potential and importance. The stock has surged 207.1% year-to-date.

Alphamab Oncology jumps on progress of ovarian cancer drug